The Benefits of Using Continuous Glucose Monitoring to Diagnose Type 1 Diabetes
J Diabetes Sci Technol
.
2024 Oct 12:19322968241288923.
doi: 10.1177/19322968241288923.
Online ahead of print.
Authors
Alessandra T Ayers
1
,
Cindy N Ho
1
,
Jenise C Wong
2
,
David Kerr
3
,
Julia K Mader
4
,
David C Klonoff
5
Affiliations
1
Diabetes Technology Society, Burlingame, CA, USA.
2
Division of Endocrinology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
3
Center for Health Systems Research, Sutter Health, Santa Barbara, CA, USA.
4
Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
5
Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA.
PMID:
39394887
PMCID:
PMC11571629
DOI:
10.1177/19322968241288923
No abstract available
Keywords:
CGM; T1D; islet autoantibody; stage 2 T1D; teplizumab.
Publication types
Editorial